The CEO's large option exercise and concurrent sales under a 10b5-1 plan are routine for tax/estate planning, but the director's non-plan sale adds a modest bearish signal. Monitor for any further insider sales or changes to the $2.0B buyback authorization announced with earnings.
Price Chart
How similar events traded
Executive Summary
CEO Martine Rothblatt executed a large option exercise and sold a portion of the resulting shares, totaling approximately $6.6M in open-market sales over two days, alongside smaller sales by the EVP/General Counsel and a director. The CEO's sales were under a 10b5-1 plan, while the director's sale was not. The cluster follows Q3 earnings that beat revenue consensus but missed EPS estimates due to a $130M in-process R&D charge.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt exercised 28,500 derivative shares (9,500 each on Nov 11 and 12, plus 9,500 on Nov 12 at $0 strike) and sold 11,927 open-market shares on Nov 11-12 for ~$6.6M total, all under a 10b5-1 plan.
- Director Christopher Patusky sold 1,200 shares open-market on Nov 9 for $702K, not under a 10b5-1 plan.
- EVP & General Counsel Paul Mahon sold 526 shares open-market on Nov 5 for $312K, under a 10b5-1 plan.
- Total open-market sales by the three insiders in the cluster window: ~$7.6M, representing approximately 0.03% of UTHR's $25.4B market cap.
- Q3 2026 revenue of $832.5M beat the $781.1M consensus, but GAAP EPS of $5.71 missed the $6.04 consensus due to a $130M in-process R&D charge from the Thymmune acquisition.
Financial Impact
Total open-market insider sales of ~$7.6M, or 0.03% of market cap. CEO's sales alone were ~$6.6M.
Risk Factors
- CEO's sales under a 10b5-1 plan reduce signaling value but still reduce her economic exposure.
- Director Patusky's non-plan sale could indicate personal concern about valuation or business outlook.
- Q3 EPS miss due to acquisition charges may weigh on near-term sentiment despite revenue beat.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1794605677050 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Viewing Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers